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Abstract
SIRT1 polymorphisms have previously been associated with depressive and anxiety disor-
ders. We aimed at confirming these earlier findings and extending the analyses to seasonal
variations in mood and behavior. Three tag single-nucleotide polymorphisms (SNPs) were
selected to capture the common variation in the SIRT1 gene. 5910 individuals (with blood
sample, diagnostic interview, self-report of on seasonal changes in mood and behavior)
were selected from a representative Finnish nationwide population-based sample. Logistic
and linear regression models were used to analyze the associations between the SNPs and
depressive and anxiety disorders, metabolic syndrome (EGIR criteria) and its components,
and health examination measurements, Homeostasis Model Assessments, and diagnoses
of type 2 and type 1 diabetes. SIRT1 rs2273773 showed evidence of association with sea-
sonal variation in weight (C-allele, OR = 0.85, 95% CI = 0.76–0.95, p = 0.005). In addition,
our study gave further support for the association of SIRT1 gene with depressive disorders
(rs3758391) and diastolic blood pressure (rs2273773).
Introduction
Many recent studies have focused on sirtuin 1 (SIRT1) in relation to metabolism, insulin resis-
tance, cancer, and longevity [1–3]. SIRT1, which is a histone deacetylase, participates through
its deacetylase activity for tens of substrates in the coordination of a range of cellular functions,
such as cell-division cycle, response to DNA damage, apoptosis, and autophagy. SIRT1 is also a
sensor of the cytosolic housekeeping redox reaction of nicotinamide adenine dinucleotide that
is measured with the ratio of the oxidized and the reduced forms, and that is changed by glu-
cose deprivation and the metabolic changes under caloric restriction or fasting. There is an ear-
lier report on SIRT1 in metabolic syndrome, where there was no significant association [4].
So far, genetic variations in SIRT1 have been associated with depressive [5] and anxiety [6]
disorders. In an elegant study, both common and rare variations in SIRT1 in humans were
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found to associate with the increased odds for anxiety disorders at large [6]. The study also
demonstrated that in mice SIRT1 increases anxiety by deacetylating the brain-specific helix-
loop-helix transcription factor, nescient helix loop helix 2 (NHLH2), which increases its activ-
ity on the monoamine oxidase A (MAOA) promoter. As the MAOA enzyme degrades seroto-
nin and dopamine, the increased enzyme activity leads to reduced serotonin and dopamine
levels in the brain, especially in those regions related to regulation of mood and emotions, and
thereby to increased depression and anxiety [7–9].
Further, SIRT1 variants have been associated with depressive disorder [5], but not with
bipolar disorder [10]. However, during a depressive episode due to major depressive disorder
or bipolar disorder, the mRNA levels of sirtuin isoforms in peripheral white blood cells, are
lowered whereas the levels of those mRNAs in a remissive state are equal to those in healthy
controls [11]. Here, it is of note that 10–20% of patients with recurrent major depressive disor-
der and 15–22% of those with bipolar disorder have the seasonal pattern for mood disorder, or
seasonal affective disorder [12].
It appears that not only mood and behavior, but also the components, or risk factors, of the
metabolic syndrome of the individual do fluctuate over the year. The increase in metabolic syn-
drome prevalence is mainly due to the increases in blood pressure and glucose during the win-
ter, and the seasonal variation in metabolic syndrome prevalence associates with insulin
resistance being increased from the extent of mild to moderate [13,14].
One aim of our current study was to confirm, as far as SIRT1 is concerned, the earlier find-
ings that have demonstrated associations of sirtuins with depressive and anxiety disorders.
Another aim of our current study was to extend the exploration of associations of SIRT1 to
concern those with the seasonal variations in mood and behavior, metabolic disorder, and rele-
vant health examination measurements. Here, we report associations to seasonal variation in
weight, depressive disorders and diastolic blood pressure.
Materials and Methods
Subjects
The subjects were selected from the national Health 2000 survey [15] of Finnish population
aged 30 years and older (n = 8028) living in mainland Finland that was approved by the ethics
committees of the National Public Health Institute and the Helsinki and Uusimaa Hospital
District. All participants provided a written informed consent. The selection (n = 5910)
included individuals who had given blood samples, taken part to the Munich-Composite Inter-
national Diagnostic Interview (M-CIDI) [15] and filled in the self-report on seasonal changes
in mood and behavior adapted from the Seasonal Pattern Assessment Questionnaire
(SPAQ) [16].
Phenotypes
Depressive disorders (major depressive disorder, dysthymia) and anxiety disorders (panic dis-
order w/o agoraphobia, generalized anxiety disorder, social phobia, agoraphobia) without hier-
archy criteria were assessed using M-CIDI, a valid and reliable instrument for the assessment
of depressive, anxiety and alcohol use disorders yielding diagnoses according to Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [16]. The controls did not
have any diagnosis of mental disorders nor met any sub-threshold criteria as assessed with the
M-CIDI.
The participants filled in a questionnaire of lifetime seasonal variations in mood and behav-
ior adapted from SPAQ [17]. The six items of sleep length, social activity, mood, weight, appe-
tite, and energy level were scored from 0 to 3 (none, slight, moderate or marked change) rather
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than from 0 to 4 (none, slight, moderate, marked or extremely marked change), with the sum
or global seasonality score (GSS) then ranging from 0 to 18. The psychometric properties of
this modified questionnaire have been reported to be good [18]. In this study, dichotomous
variables (no variation, variation) were computed for the six items.
Routine fasting laboratory tests included the concentrations of blood glucose, serum insulin,
serum total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-den-
sity lipoprotein (HDL) cholesterol. The Homeostasis Model Assessment (HOMA) insulin
resistance and beta-cell function indexes were computed. Blood pressure, height, weight, and
waist circumference were measured. Body-mass index (BMI) was calculated (as kg per m2).
Diagnosis of type 2 diabetes and that of type 1 diabetes were assessed on the basis of all avail-
able data collected for the health examination study (for details of the methods, see http://
www.terveys2000.fi/indexe.html). Using these data, the metabolic syndrome was assessed with
the criteria of European Group for the Study of Insulin Resistance (EGIR) modification of
World Health Organization (WHO) criteria: diabetics and highest quartile of non-diabetics for
fasting glucose were excluded. To fulfill the EGIR criteria for the metabolic syndrome, two of
the following needed to be present: Fasting glucose of6.1 mmol/l, elevated blood pressure
(mean of systolic blood pressure measurements of140 mmHg, or mean of diastolic blood
pressure measurements of90 mmHG, or medication for hypertension), triglycerides of2.0
mmol/l or HDL of1.0 mmol/l or lipid-lowering medication, waist circumference of94 cm
for men and that of80 cm for women.
Gene and SNP selection
SIRT1 SNP selection was based on HapMap phase 3 data (http://www.hapmap.org/) and tag-
ging was done using the Tagger program in the Haploview 4.2 software [19]. The linkage dis-
equilibrium (LD) within the gene and 10 kb of their 5' and 3' flanking regions, i.e. 54 kb
(chr10:69,304–69,358 kb, NCBI36/hg18 assembly), was used to select tag SNPs capturing most
of the genetic variation. The aim was to capture all the SNPs having a minor allele frequency
(MAF) of>5% in the European population (CEU and TSI) in the HapMap database. The pair-
wise r2 was set to0.9 in order to select a tag SNP among the SNPs that were in LD. Four out
of 19 SIRT1 SNPs fulfilled the criterion, and three SNPs (rs3758391, rs2273773, rs17454621)
were successfully included in the genotyping multiplex.
Genotyping
Genomic DNA was isolated from whole blood according to standard procedures. The SNPs
were genotyped at the Institute for Molecular Medicine Finland, Technology Centre, Univer-
sity of Helsinki using the MassARRAY iPLEX method (Sequenom, San Diego, CA, USA) [20],
with excellent success (>95%) and accuracy (100%) rates [21]. For quality control purposes,
positive (CEPH) and negative water controls were included in each 384-plate. Genotyping was
performed blind to phenotypic information.
440 of 5910 individuals were removed due to a high missing genotype rate (i.e.>0.1). The
total genotyping rate in the remaining individuals was 0.996. Finally, there were 5470 individu-
als and three SIRT1 SNPs for the statistical analyses.
Statistical analyses
Statistical analyses were performed using logistic or linear regression and additive genetic
model. Unadjusted, age and sex adjusted, and age, sex and BMI adjusted models were calcu-
lated using PLINK software v1.07 [22]. The values presented in the text are from the age and
sex adjusted models. Haplotype blocks were defined using Haploview software [19] and the
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confidence interval algorithm. For the continuous phenotypes (GSS, BMI, waist circumference,
diastolic and systolic blood pressure, blood glucose, insulin resistance index, beta-cell index,
LDL, total cholesterol, HDL, insulin, triglycerides) 10,000 permutations were used to produce
empirical p-values in order to relax the assumption of normality. The p-values were corrected
for multiple testing with the Bonferroni method by taking into account the number of SNPs
and independent phenotypes. After the Bonferroni correction, p-values of<0.0056 are signifi-
cant for seasonality, p<0.0071 for metabolic syndrome and p<0.0029 for health examination
measurements, HOMAs, and diagnoses of type 2 and type 1 diabetes. For replication of the
previous findings reported in the literature, i.e. depressive and anxiety disorders, p-values
of<0.05 were considered significant. Population stratification was not addressed.
Results
The participants’ general characteristics are reported in Table 1. The study population of 5910
subjects was 55.4% women and had a mean age of 53.1 years (SD = 15.0), BMI of 27.0
(SD = 4.7), GSS of 5.0 (SD = 3.0), blood pressure of 81.7/134.9 (SD = 11.3/21.3). 8.2% had
depressive disorder, 5.3% had anxiety disorder, 23.2% had metabolic syndrome (EGIR). Most
participants presented seasonal variations in sleep length, social activity, mood and energy
level.
Genotype and allele frequencies and the Hardy-Weinberg equilibrium estimates are shown
in Table 2. No haplotype blocks were formed for SIRT1 (Fig 1). All the SNP association results
are shown in S1 Table. SIRT1 rs3758391 T allele showed nominally significant associations
with depressive disorders (OR = 1.19, 95% CI of 1.01 to 1.40, p = 0.040, see Table 3), metabolic
syndrome (OR = 0.88, 95% CI of 0.80 to 0.97, p = 0.01, see Table 3), insulin resistance index
(beta = -0.26, 95% CI of -0.48 to -0.04, p = 0.019, empirical p = 0.02, see Table 3) and blood glu-
cose (beta = -0.05, CI of -0.09 to -0.002, p = 0.04, empirical p = 0.04, Table 3). The associations
with metabolic syndrome, insulin resistance index and blood glucose did not remain significant
after correcting for multiple testing.
The association of SIRT1 rs2273773 with the seasonal variation in weight (OR = 0.85, 95%
CI of 0.76 to 0.95, p = 0.005) remained significant after the Bonferroni correction, the C-allele
being associated with the decreased odds for the seasonal variation in weight (Table 3). SIRT1
rs2273773 C allele associated with both high diastolic (beta = 1.06, 95% CI of 0.43 to 1.68,
p = 0.001, empirical p-value = 0.001) and systolic blood pressure (beta = 1.23, 95% CI of 0.19
to 2.28, p = 0.02, empirical p-value = 0.02), of which the association with diastolic blood pres-
sure remained significant after the Bonferroni correction, the C-allele having the odds for
higher diastolic blood pressure.
Table 2. SIRT1 genotype counts and frequencies and Hardy-Weinberg equilibrium p-values. BP; Base
pair position. A1; Minor allele. A2; Major allele. MAF; Minor allele frequency. A1A1, A1A2, A2A2; Genotype
counts and frequencies (%). P; Hardy-Weinberg p-value
SNP BP (NCBI36/hg18) A1 A2 MAF A1A1 (%) A1A2 (%) A2A2 (%) P
rs3758391 69313348 T C 38.9 832 (15.2) 2581 (47.3) 2045 (37.5) 0.71
rs2273773 69336604 C T 12.6 95 (1.7) 1180 (21.6) 4182 (76.6) 0.27
rs17454621 69356812 C T 9.1 40 (0.7) 909 (16.6) 4513 (82.6) 0.51
doi:10.1371/journal.pone.0141001.t002
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Discussion
Our current results from the population-based health examination study suggested the minor
C-allele of synonymous (Leu!Leu) SIRT1 rs2273773 polymorphism to contribute to higher
diastolic blood pressure, and to protect from seasonal variation in body weight. However, the
SNP showed no evidence of association with BMI or the metabolic syndrome or its compo-
nents, as assessed with the EGIR modification of WHO criteria. In agreement, CC carriers have
previously been reported to have high systolic and diastolic blood pressures in men [23], and
no association with metabolic syndrome in morbidly obese subjects has been found [24].
However, the C-allele (or CC genotype or C carriers) has been reported to be protective against
cardiovascular diseases [25] and contribute to higher energy expenditure [26], a lower BMI
[27], and lower fasting glucose concentrations and body fat ratios in men [23]. Moreover, the
Fig 1. The SIRT1 SNPs analyzed and their location showing r2 values. The confidence interval algorithm
implemented in the Haploview program was used to construct the haplotype blocks.
doi:10.1371/journal.pone.0141001.g001
Table 3. Results (P/EMP<0.05) of the SIRT1 SNP associations (unadjusted on the first line / age and
sex adjusted on the second line / age, sex and BMI adjusted on the third line). A1; Tested allele (minor
allele). N; Number of genotypes for the phenotype. L95, U95; Lower and upper bounds of 95% confidence
interval for odds ratio. P/EMP: p-value / empirical p-value
Phenotype SNP A1 N OR/beta L95 U95 P EMP
Depressive and anxiety disorders
Depressive disorders RS3758391 T 3911 1.18 1.00 1.39 0.05
1.19 1.01 1.40 0.04
1.19 1.01 1.40 0.04
Metabolic syndrome (EGIR) and its components
Metabolic syndrome RS3758391 T 5046 0.90 0.82 0.99 0.03
0.88 0.80 0.97 0.01
0.86 0.77 0.96 0.01
Seasonal variations in mood and behavior
Weight RS2273773 C 5322 0.84 0.75 0.95 0.003
0.85 0.76 0.95 0.01
0.86 0.76 0.97 0.01
Health examination measurements, HOMAs, and diagnoses of type 2 and type 1 diabetes.
Diastolic blood pressure RS2273773 C 5438 1.13 0.49 1.76 0.001 0.001
1.06 0.43 1.68 0.001 0.001
1.23 0.63 1.82 0.0001 0.0003
Systolic blood pressure RS2273773 C 5440 1.88 0.68 3.08 0.002 0.003
1.23 0.19 2.28 0.02 0.02
1.46 0.45 2.48 0.005 0.004
Insulin resistance index RS3758391 T 5331 -0.25 -0.47 -0.03 0.03 0.02
-0.26 -0.48 -0.04 0.02 0.02
-0.28 -0.49 -0.06 0.01 0.01
Blood glucose RS3758391 T 5454 -0.04 -0.09 0.009 0.11 0.11
-0.05 -0.09 -0.002 0.04 0.04
-0.05 -0.09 -0.002 0.04 0.04
doi:10.1371/journal.pone.0141001.t003
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T-allele of SIRT1 rs2273773 was seen, as part of two haplotypes of SIRT1, to be associated with
schizophrenia but not with bipolar disorder [10]. We were not able to test this association,
since these disorders were not assessed with the method used for diagnostic interview in our
study. In addition, our study provides further support of the association between SIRT1
(rs3758391) and depressive disorders (major depressive disorder and dysthymia).
Our study does not come without limitations. The assessment of the seasonal variations in
mood and behavior was based on the self-report only and only limited variables were con-
trolled for in the statistical analysis. On the other hand, there are strengths in our study such as
the number of participants enrolled from a nation-wide and representative sample of the adult
general population aged 30 years and older, the health examination protocol for the assessment
of the metabolic syndrome, the diagnostic interview for the assessment of depressive and anxi-
ety disorders, and the coverage of SIRT1 for the assessment of genetic association.
In conclusion, we found that SIRT1 (rs2273773) accounts for the seasonal variation in body
weight. In addition, our study gave further support for the role of SIRT1 in depressive disorders
(rs3758391) and diastolic blood pressure (rs2273773). Thus, SIRT1 appears to contribute to
seasonal, mood and cardiovascular physiology in humans.
Supporting Information
S1 Table. All results of the SIRT1 SNP associations.
(XLSX)
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